Royalty Report: Drugs, Multiple Sclerosis, Disease – Collection: 327223


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 12


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 12

Primary Industries

  • Drugs
  • Multiple Sclerosis
  • Disease
  • Therapeutic
  • Pharmaceuticals
  • Pain
  • Drug Discovery
  • Biotechnology
  • Cancer

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 327223

License Grant
The agreement is an exclusive global license agreement for the rights to a U.S. patent.
License Property
Licensor is the owner of Patent 10,610,592, titled Treatment of multiple sclerosis.

Multiple Sclerosis (MS) is a chronic disease in which the immune system of the individual attacks the central nervous system and affects the nerve cells. The disease can manifest with a wide range of neurological symptoms and can progress to total physical and cognitive disability. There are many different symptoms of MS, including fatigue, numbness, walking and balance problems, bladder dysfunction, bowel dysfunction, vision problems, dizziness and vertigo, sexual dysfunction, pain, cognitive dysfunction, emotional changes, depression and spasticity.

Field of Use
The field of use is for the treatment of Multiple Sclerosis.

IPSCIO Record ID: 26724

License Grant
This License Agreement provides for worldwide distribution rights for so long as there are patent rights and the parties continue their corporate existence.
License Property
BOW 304 is a drug being developed for the treatment of Multiple Sclerosis and related neurological symptoms.  The product is to be developed through a joint development and marketing agreement with a British based research and development partnership.

Chronic progressive multiple sclerosis (MS) is a severely disabling demyelinating disease in which autoimmune processes seem to have a major role in the destruction of brain and nerve tissue. Treatment options are limited although beta-interferon has been widely reported to have some beneficial effect in MS. It is assumed that beta interferon has its action on the cells of the immune system that are attacking the patient’s nerve tissue.

Field of Use
The rights granted relate to neurological symptoms.

IPSCIO Record ID: 797

License Grant
The Licensor grants the Licensee exclusive, nontransferable Licenses for the Applications and the Patents; and the Trademarks, until the Patents expire.

The grant of each License hereunder includes the right to grant subLicenses to Related Companies.

License Property
Applications means PCT/US2009/062895, entitled Medication and Treatment for Disease.

Trademarks mean Feldetrexâ„¢, including US Trademark Application No. 77/601,101 and any identical marks later filed in countries other than the United States of America.

Feldetrexâ„¢ drug is a proprietary combination of generic medications which is believed to reduce the symptomatology of Multiple Sclerosis, Fibromyalgia, and Traumatic Brain Injury.
Multiple Sclerosis is a chronic, progressive illness that affects the nerves in the brain, spinal cord, and other parts of the central nervous system.
Fibromyalgia (FM or FMS) is characterized by chronic widespread pain and allodynia (a heightened and painful response to pressure).[1] Its exact cause is unknown but is believed to involve psychological, genetic, neurobiological and environmental factors.

Field of Use
Trial usage of Feldetrex â„¢ has been used in patients with Multiple Sclerosis.

Licensee shall prominently use the Trademark on Licensed Products.

IPSCIO Record ID: 301608

License Grant
Danish Licensee acquires the patent family from Swiss Licensor, a related party. Under the Transfer Agreement, the Company obtained, among other things, Licensors patents and associated know-how related to DMF formulations and delivery systems (the Licensor IP).
License Property
Dimethyl fumarate (DMF), an immunomodulator, as a therapeutic to improve the health of patients with immune disorders, including MS.  Dimethyl fumarate (DMF) is the methyl ester of fumaric acid.

Licensor develops and files patents for, among other things, formulations and dosing regimens of DMF.

Field of Use
Dimethyl fumarate is used to treat adults with various forms of multiple sclerosis (MS; a disease in which the nerves do not function properly and people may experience weakness, numbness, loss of muscle coordination, and problems with vision, speech, and bladder control)

IPSCIO Record ID: 329689

License Grant
Licensor of Ireland grants an exclusive license under the Licensor Intellectual Property in the Territory to package, use, import, export, promote, distribute, offer for sale, sell and otherwise exploit and, solely as permitted in the Supply Agreement, to make and have made
– the Fampridine Product in the SCI Field for the SCI Term;
– the Fampridine Product in the MS Field for the MS Term; and
– without prejudice, the Product in the SCI Field, MS Field and/or Other Indication Field for the Other Indication Term, subject to any contractual obligations with respect to a formulation using Nanoformulation technology in the Other Indication Field.

Licensor grants a non-exclusive royalty free license in the Territory solely for use in connection with the sale of the Product, for the term of this Agreement to use any trademark which relates to the Licensor technology applicable to the Product.

License Property
The Compound shall mean 4-aminopyridine as well as the isomers, and the salts thereof.

Fampridine Product shall mean any finished pharmaceutical oral sustained release dosage form containing the Compound, which is in the scope of one or more Valid Claims within the Licensor Patent Rights in the country of sale, and/or incorporates Licensor Know-How in material part. The use of the pre-clinical, toxicological, pharmacokinetic, metabolic, formulation, methods, clinical protocols and data developed for and on behalf of Licensor, which is included in the Licensor Know-How shall constitute incorporation of the Licensor Know-How in material part.

Licensee patents used are Treating Diseases of the Anterior Horn Cells, and, the use of  4-Aminopyridine in the treatment of a neurological condition.

Licensors patents include Matrix Formulation of Potassium Chemical Blockers (Fampridine)

Field of Use
Fampridine is a drug that has been shown to improve walking speed for some adults with multiple sclerosis.

The field of use Indication shall mean any use or indication of Product for treatment of any condition, including spinal cord injury (SCI) and multiple sclerosis (MS).

MS Field shall mean use as an oral prescription medicine fort he treatment of MS in humans.

SCI Field shall mean use as an oral prescription medicine for the treatment of SCI in humans.

Other Indication Field shall mean use as a prescription medicine for the treatment of any condition in humans, excluding the SCI Field and the MS Field, but for the avoidance of doubt including the treatment of SCI and/or MS otherwise than orally.

IPSCIO Record ID: 376285

License Grant
University granted the Licensee an exclusive, worldwide, sublicensable, royalty-bearing license to certain intellectual property (i) to make, have made, use, sell, offer to sell, and import certain licensed products and (ii) to use the invention titled, “Central nervous system-homing peptides in vivo and their use for the investigation and treatment of multiple sclerosis and other neuroinflammatory pathology” and Universitys confidential information to develop and perform certain licensed processes for the therapeutic treatment of neuroinflammatory disease.
License Property
Central nervous system (CNS)-homing peptide (MS-1) is being studied to effectively deliver dexamethasone to the CNS. For targeted drug delivery, a drug for MS will be incorporated within a nanoparticle, which displays a CNS-homing peptide (MS-1) on its surface. In addition, this nanoparticle will have polyethylene glycol (PEG) on its surface to minimize the otherwise rapid clearance of the particles by the reticuloendothelial system.
Field of Use
Field of use is for the investigation and treatment of multiple sclerosis and other neuroinflammatory pathology.

Multiple sclerosis (MS) is an autoimmune disease affecting the central nervous system (CNS). Inflammation and demyelination of neurons resulting from a self-directed immune attack leads to muscle weakness and paralysis.

IPSCIO Record ID: 292649

License Grant
The Company received an exclusive, worldwide license to develop and commercialize VUMERITY.
License Property
VUMERITY is novel fumarate for the treatment of RMS (relapsing multiple sclerosis).
Field of Use
VUMERITY is a prescription medicine used to treat people with relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.

IPSCIO Record ID: 26620

License Grant
The Licensee has an exclusive, worldwide license from the College to develop and commercialize three technology areas for MS, namely T-cell vaccination, peptides, and diagnostics. Under the License Agreement with the College, the licensee will have rights to a total of 7 patents (2 U.S. and 5 foreign) and 69 patent applications (6 U.S., 62 foreign, and 1 Patent Cooperation Treaty [PCT]). Our multiple sclerosis cell therapy, Tovaxin, is currently in Phase I/II studies.
License Property
Tovaxin consists of modified auto reactive T cells. Multiple sclerosis is a result of a person’s own T cells attacking the myelin sheath that coats the nerve cells of the central nervous system. These T cells, that attack a person’s own body, are referred to as auto reactive T cells. In our treatment the T cells are taken from the patient, modified and returned to the patient. The modified T cells cause an immune response directed at the auto reactive T cells in the patient’s body. This immune response reduces the level of auto reactive T cells and potentially allows the myelin sheath to be repaired. In addition, we are evaluating whether this technology will allow us to diagnose multiple sclerosis and determine the severity of the disease through an analysis of the level of auto reactive T cells in a patient’s blood.

IPSCIO Record ID: 316237

License Grant
Under the terms of the Asset Purchase Agreement with Party A, the Danish Licensee became party to a royalty agreement with the Trust for worldwide net sales of Arimoclomol for the treatment of Amyotrophic Lateral Sclerosis (ALS). Pursuant to this Asset Agreement, Party A sold and transferred certain preclinical and clinical data, patents and other intellectual property rights, and other assets, including contractual rights and obligations relating to a portfolio of chemical compounds, including arimoclomol, to Licensee.
License Property
Arimoclomol is an orally- or naso/gastrically-administered small molecule that crosses the blood-brain barrier and is designed to selectively amplify the natural role of endogenous Heat Shock Proteins (HSPs), which protect against cellular toxicity caused by protein misfolding, aggregation and lysosomal dysfunction.

The Trust is the charitable remainder beneficiary that generates a potential income stream from donors, or other beneficiaries, to benefit the research of ALS.

Amyotrophic lateral sclerosis or ALS, is a progressive nervous system disease that affects nerve cells in the brain and spinal cord, causing loss of muscle control. ALS is often called Lou Gehrig's disease.

Field of Use
The Field of Use is for the treatment or prevention of Amyotrophic Lateral Sclerosis (ALS).  ALS, commonly referred to as Lou Gehrig’s disease, is a rapidly progressing neurological disease with the onset of symptoms typically occurring between 40 to 70 years of age, with patient mortality occurring in most patients within three to five years of disease onset. ALS attacks neurons responsible for controlling voluntary muscles, resulting in muscle weakness in limbs, and impacts speaking, chewing, swallowing and breathing, leading to progressive disability and eventually death, typically from respiratory failure and aspiration pneumonia.

Licensee is biopharmaceutical company harnessing the amplification of Heat Shock Proteins, or HSPs, in order to develop and commercialize novel therapeutics for the treatment of neurodegenerative orphan diseases that includes Amyotrophic Lateral Sclerosis (ALS), commonly referred to as Lou Gehrig’s disease.

IPSCIO Record ID: 7362

License Grant
Pursuant to the Agreement, the Licensee has an option to acquire an exclusive, worldwide (excluding Japan) License of our Tcelna program for the treatment of MS.
License Property
The Licensor is a biopharmaceutical company developing a personalized immunotherapy with the potential to treat major illnesses, including multiple sclerosis (MS). This therapy is based on proprietary T-cell technology. MS is a chronic, often disabling disease that affects the central nervous system. MS attacks the covering surrounding nerve cells, or myelin sheaths, leading to loss of myelin (demyelination) and nerve damage.

Tcelna is a novel T-cell immunotherapy in Phase IIb clinical development for the treatment of patients with SPMS. It is also positioned to enter Phase III clinical development for the treatment of patients with relapsing remitting MS (RRMS), subject to the availability of sufficient resources. Tcelna is a personalized therapy that is specifically tailored to each patient's disease profile. Tcelna is manufactured using ImmPathTM, our proprietary methodd for the production of a patient-specific T-cell immunotherapy which encompasses the collection of blood from the MS patient, isolation of peripheral blood mononuclear cells, generation of an autologous pool of MRTCs raised against selected peptides from myelin basic protein (MBP), myelin oligodendrocyte glycoprotein (MOG) and proteolipid protein (PLP), and the return of these expanded, irradiated T-cells back to the patient.

IPSCIO Record ID: 330325

License Grant
Licensor granted a worldwide exclusive, sublicensable license to certain Licensor owned provisional patent applications and any patents issuing therefrom, including all continuations, continuations-in-part, divisions, extensions, substitutions, reissues, re-examinations, and any applications and all patents issuing from any applications and patents that claim domestic benefit or foreign priority to the provisional patent applications.

The Agreement also grants a contingent right to License certain other University licensed Patent Rights, to negotiate with Licensor, to obtain a nonexclusive sublicense in the field of cancer and treating cancer, including neuroinflammatory diseases occurring in any patient diagnosed with cancer.

License Property
The licensed patents relate to the use of psilocybin in cancer treatment, and any patents issuing therefrom, including all continuations, continuations-in-part, divisions, extensions, substitutions, reissues, re-examinations, and any applications and all patents issuing from any applications and patents that claim domestic benefit or foreign priority to the provisional patent applications.

Psilocybin is a naturally occurring psychedelic prodrug compound.

U.S. Provisional Patent Application No. 63/060,573, titled “Central Nervous System Delivery of Psilocybin”

U.S. Provisional Patent Application No. 63/060,569, titled “Central Nervous System Delivery of Nonsteroidal Anti-Inflammatory Drugs and Psilocybin”

U.S. Provisional Patent Application No. 63/060,577, titled “Central Nervous System Delivery of Nonsteroidal Anti-Inflammatory Drugs and Psilocybin”

U.S. Provisional Patent Application No. 63/24,827, titled “Use of Psilocybin in Cancer Treatment”

Field of Use
“Field of Use” means treatment of cancer and symptoms caused by cancer, including but not limited to pain, nausea, neuroinflammation, brain and neural dysfunction, depression, seizures, confusion, dizziness, numbness/tingling, dysfunction of the senses and all other symptoms that are caused by cancer of any type. For the sake of clarity, the Field of Use does not include any potential applications of the Licensed Products and Licensed Processes other than those used in treating cancers and the symptoms caused by the cancers.

IPSCIO Record ID: 240497

License Grant
Under the terms of the collaboration agreement with Licensee, the Licensor will receive a tiered royalty for the sale of OCREVUS.
License Property
OCREVUS for the treatment of primary progressive MS (PPMS) and relapsing MS (RMS) and other potential anti-CD20 therapies.

Primary Progressive Multiple Sclerosis, MS (PPMS) is characterized by worsening neurologic function (accumulation of disability) from the onset of symptoms, without early relapses or remissions.

Field of Use
This agreement pertains to the drug industry.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.